The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to review new drug application ...

For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it ...

As a lecturer and clinical instructor in vision therapy and pediatrics, it is important to have a literature base for what I am teaching. My top 10 favorite vision therapy books provide that evidence ...

Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026. Thomas Wong, ...

Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what ...

Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia. It’s a familiar question in optometry ...

Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular ...

Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting. Although ophthalmologists use low ...

Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session. In an exclusive interview with Optometry Times, ...

Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates. Before the session, attendees ...